Heparin-binding Epidermal Growth Factor-like Growth Factor Promotes Enterocyte Migration and Proliferation in Neonatal Rats with Necrotizing Enterocolitis
Overview
Pediatrics
Authors
Affiliations
Purpose: We have shown that heparin-binding epidermal growth factor-like growth factor (HB-EGF) decreases experimental necrotizing enterocolitis (NEC). Intestinal epithelial cell (IEC) migration (restitution) and proliferation are key elements in recovery from intestinal injury. Here, we investigated whether the beneficial effects of HB-EGF are mediated, in part, by its ability to affect these processes.
Methods: Necrotizing enterocolitis was induced in newborn rats by exposure to stress (hypoxia, hypothermia, hypertonic feedings, and lipopolysaccharide), with pups receiving different doses of HB-EGF (0, 25, 50, 100, 200, 400, 600, and 800 microg/kg). To investigate the effect of HB-EGF on enterocyte proliferation and migration, bromodeoxyuridine was administered intraperitoneally 18 hours before sacrifice, with intestine subjected to bromodeoxy-uridine immunohistochemistry.
Results: The incidence and severity of experimental NEC decreased, and the survival rate increased, with increasing doses of HB-EGF. Results were confirmed using scanning electron microscopy. Migration of IEC in breast-fed pups was 7.07 microm/h, decreased significantly to 2.29 microm/h in stressed pups, and was significantly improved at 5.95 microm/h in pups subjected to stress but treated with HB-EGF (P < .05). Quantification of IEC proliferation revealed 208 (+) cells per high-power field (HPF) in breast-fed pups, which decreased significantly to 99 (+) cells per HPF in stressed pups and increased to 190 (+) cells per HPF in stressed pups treated with HB-EGF (P < .05).
Conclusions: These results demonstrate that HB-EGF protects newborn rats from experimental NEC in a dose-dependent fashion. The ability of HB-EGF to protect the intestines from NEC is due, in part, to the ability of HB-EGF to preserve enterocyte migration and proliferation.
Zhang Y, Yan M, Yue Y, Cheng Y Mediators Inflamm. 2024; 2024:4811500.
PMID: 39719983 PMC: 11668547. DOI: 10.1155/mi/4811500.
Knockout Genes in Bowel Anastomoses: A Systematic Review of Literature Outcomes.
Geropoulos G, Psarras K, Koimtzis G, Fornasiero M, Anestiadou E, Geropoulos V J Pers Med. 2024; 14(6).
PMID: 38929776 PMC: 11205243. DOI: 10.3390/jpm14060553.
Zhang Y, Yan M, Xia Y, Yue Y, Wang S, Hu Y Mol Ther Methods Clin Dev. 2024; 32(1):101214.
PMID: 38496303 PMC: 10940916. DOI: 10.1016/j.omtm.2024.101214.
Recombinant IGF-1/BP3 protects against intestinal injury in a neonatal mouse NEC model.
Yan X, Managlia E, Carey G, Barton N, Tan X, De Plaen I Pediatr Res. 2024; 95(7):1803-1811.
PMID: 38418592 PMC: 11894450. DOI: 10.1038/s41390-024-03069-8.
Mesfin F, Manohar K, Shelley W, Brokaw J, Liu J, Ma M Semin Pediatr Surg. 2023; 32(3):151311.
PMID: 37276782 PMC: 10330659. DOI: 10.1016/j.sempedsurg.2023.151311.